1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Development & Drug Target
1.4.3 Mechanism of Action (MoA)
1.4.4 Route of Administration (RoA)
1.4.5 Molecule Type
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2021-2026
1.5.2 Hospitals and Clinics
1.5.3 Medical Laboratories
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Duchenne Muscular Dystrophy Drugs Market
1.8.1 Global Duchenne Muscular Dystrophy Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Duchenne Muscular Dystrophy Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Duchenne Muscular Dystrophy Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Duchenne Muscular Dystrophy Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America Duchenne Muscular Dystrophy Drugs Sales Volume
3.3.1 North America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume
3.4.1 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.5.1 Europe Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.6.1 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.8.1 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.9.1 Africa Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.10.1 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.11.1 South America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Duchenne Muscular Dystrophy Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Duchenne Muscular Dystrophy Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Duchenne Muscular Dystrophy Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Duchenne Muscular Dystrophy Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Duchenne Muscular Dystrophy Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Duchenne Muscular Dystrophy Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Duchenne Muscular Dystrophy Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global Duchenne Muscular Dystrophy Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Duchenne Muscular Dystrophy Drugs Consumption Volume by Application (2015-2020)
15.2 Global Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Duchenne Muscular Dystrophy Drugs Business
16.1 Akashi Therapeutics Inc
16.1.1 Akashi Therapeutics Inc Company Profile
16.1.2 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Capricor Therapeutics Inc
16.2.1 Capricor Therapeutics Inc Company Profile
16.2.2 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.2.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Biogen Inc
16.3.1 Biogen Inc Company Profile
16.3.2 Biogen Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.3.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Antisense Therapeutics Ltd
16.4.1 Antisense Therapeutics Ltd Company Profile
16.4.2 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.4.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Biophytis SAS
16.5.1 Biophytis SAS Company Profile
16.5.2 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Specification
16.5.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Beech Tree Labs Inc
16.6.1 Beech Tree Labs Inc Company Profile
16.6.2 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.6.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 CRISPR Therapeutics
16.7.1 CRISPR Therapeutics Company Profile
16.7.2 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Specification
16.7.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 BioMarin Pharmaceutical Inc
16.8.1 BioMarin Pharmaceutical Inc Company Profile
16.8.2 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.8.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Bioleaders Corp
16.9.1 Bioleaders Corp Company Profile
16.9.2 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Specification
16.9.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Catabasis Pharmaceuticals Inc
16.10.1 Catabasis Pharmaceuticals Inc Company Profile
16.10.2 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.10.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Eloxx Pharmaceuticals Inc
16.11.1 Eloxx Pharmaceuticals Inc Company Profile
16.11.2 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.11.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Fulcrum Therapeutics Inc
16.12.1 Fulcrum Therapeutics Inc Company Profile
16.12.2 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.12.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Cumberland Pharmaceuticals Inc
16.13.1 Cumberland Pharmaceuticals Inc Company Profile
16.13.2 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.13.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Genethon SA
16.14.1 Genethon SA Company Profile
16.14.2 Genethon SA Duchenne Muscular Dystrophy Drugs Product Specification
16.14.3 Genethon SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 F. Hoffmann-La Roche Ltd
16.15.1 F. Hoffmann-La Roche Ltd Company Profile
16.15.2 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.15.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Editas Medicine Inc
16.16.1 Editas Medicine Inc Company Profile
16.16.2 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.16.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Daiichi Sankyo Co Ltd
16.17.1 Daiichi Sankyo Co Ltd Company Profile
16.17.2 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.17.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Galapagos NV
16.18.1 Galapagos NV Company Profile
16.18.2 Galapagos NV Duchenne Muscular Dystrophy Drugs Product Specification
16.18.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 FibroGen Inc
16.19.1 FibroGen Inc Company Profile
16.19.2 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.19.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.20 Debiopharm International SA
16.20.1 Debiopharm International SA Company Profile
16.20.2 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Specification
16.20.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.21 Taiho Pharmaceutical Co Ltd
16.21.1 Taiho Pharmaceutical Co Ltd Company Profile
16.21.2 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.21.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.22 GTx Inc
16.22.1 GTx Inc Company Profile
16.22.2 GTx Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.22.3 GTx Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.23 Summit Therapeutics Plc
16.23.1 Summit Therapeutics Plc Company Profile
16.23.2 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Specification
16.23.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.24 Strykagen Corp
16.24.1 Strykagen Corp Company Profile
16.24.2 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Specification
16.24.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.25 WAVE Life Sciences Ltd
16.25.1 WAVE Life Sciences Ltd Company Profile
16.25.2 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.25.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.26 SOM Biotech SL
16.26.1 SOM Biotech SL Company Profile
16.26.2 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Specification
16.26.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.27 Santhera Pharmaceuticals Holding AG
16.27.1 Santhera Pharmaceuticals Holding AG Company Profile
16.27.2 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Specification
16.27.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.28 Teijin Pharma Ltd
16.28.1 Teijin Pharma Ltd Company Profile
16.28.2 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Specification
16.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.29 Sarepta Therapeutics Inc
16.29.1 Sarepta Therapeutics Inc Company Profile
16.29.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification
16.29.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Duchenne Muscular Dystrophy Drugs Manufacturing Cost Analysis
17.1 Duchenne Muscular Dystrophy Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs
17.4 Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Duchenne Muscular Dystrophy Drugs Distributors List
18.3 Duchenne Muscular Dystrophy Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Duchenne Muscular Dystrophy Drugs (2021-2026)
20.2 Global Forecasted Revenue of Duchenne Muscular Dystrophy Drugs (2021-2026)
20.3 Global Forecasted Price of Duchenne Muscular Dystrophy Drugs (2015-2026)
20.4 Global Forecasted Production of Duchenne Muscular Dystrophy Drugs by Region (2021-2026)
20.4.1 North America Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.2 East Asia Market Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.3 Europe Market Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Countriy
21.4 South Asia Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.6 Middle East Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.7 Africa Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.8 Oceania Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.9 South America Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
21.10 Rest of the world Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer